A Study of HLX105 in Patients With Advanced or Metastatic Solid Tumors

November 17, 2026 updated by: Shanghai Henlius Biotech

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX105 (Anti-PD-1 Antibody-IL-2 Variant Fusion Protein) in Advanced/Metastatic Solid Tumors

This is an open-label, first-in-human, Phase 1 study of HLX105, an anti-PD-1 antibody-IL-2 variant fusion protein, in adults with advanced or metastatic solid tumors that have progressed after standard treatment or for which no standard treatment is available. The main purpose is to evaluate the safety and tolerability of HLX105 and determine its maximum tolerated dose. The study will also assess how the body processes HLX105, whether antibodies against HLX105 develop, preliminary antitumor activity, and changes in immune cells and other biomarkers.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

42

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Able to provide written informed consent and comply with study requirements.
  • Aged 18-75 years.
  • Histologically or cytologically confirmed advanced or metastatic solid tumors following failure of standard treatment, or for which no standard treatment is available.
  • At least one measurable extracranial lesion according to RECIST v1.1.
  • ECOG performance status of 0-1 and life expectancy greater than 3 months.
  • Willing to provide adequate archived tumor tissue or undergo a tumor biopsy.
  • Adequate organ function;
  • Agreement to comply with protocol-defined contraception requirements during the study and for at least 6 months after the last dose.

Exclusion Criteria:

  • Other malignancies within the past 2 years, except protocol-permitted early-stage cancers treated curatively.
  • Prior IL-2/IL-15 therapy, or recent anticancer treatment, surgery, or live vaccination within protocol-defined washout periods.
  • History of significant immunotherapy-related toxicity, severe allergic reactions, or allergy to HLX105 components.
  • History or evidence of interstitial lung disease or other significant pulmonary conditions.
  • Active infections, immunodeficiency, prior organ transplantation, or HBV/HCV infection meeting protocol-defined exclusion criteria.
  • Significant cardiovascular, cerebrovascular, or thromboembolic disease.
  • Brain metastases not meeting protocol-defined stability and eligibility requirements.
  • Uncontrolled effusions or unresolved toxicity from prior treatment, except protocol-permitted conditions.
  • Pregnancy or breastfeeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Dose Escalation

This study is an open-label first-in-human Phase I Clinical trial to evaluate the safety and tolerability of HLX105 with escalated doses in the treatment of participants with advanced/metastatic solid tumors.

HLX105 will be administered as an intravenous(IV) infusion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Dose-limiting toxicity (DLT)
Time Frame: The first 21 days starting with the first dose for participants dosed every 3 weeks, and the first 28 days starting with the first dose for participants dosed every 2 weeks.
The first 21 days starting with the first dose for participants dosed every 3 weeks, and the first 28 days starting with the first dose for participants dosed every 2 weeks.
Maximum tolerated dose(MTD)
Time Frame: Up to approximately 2 years
Up to approximately 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of response (DOR)
Time Frame: Up to approximately 2 years
Up to approximately 2 years
Number of participants with adverse events(AEs)
Time Frame: Up to approximately 2 years
Up to approximately 2 years
Number of participants with serious adverse events(SAEs)
Time Frame: Up to approximately 2 years
Up to approximately 2 years
Objective response rate(ORR)
Time Frame: Up to approximately 2 years
Up to approximately 2 years
Disease control rate(DCR)
Time Frame: Up to approximately 2 years
Up to approximately 2 years
Progression-free survival(PFS)
Time Frame: Up to approximately 2 years
Up to approximately 2 years
Overall survival(OS)
Time Frame: Up to approximately 2 years
Up to approximately 2 years
Cmax
Time Frame: Up to approximately 2 years

Maximum serum concentration (Cmax) of HLX105

Up to approximately 2 years
Tmax
Time Frame: Up to approximately 2 years

Time to maximum serum concentration (Tmax) of HLX105

Up to approximately 2 years
T1/2
Time Frame: Up to approximately 2 years

Half-life (T1/2) of HLX105

Up to approximately 2 years
Percentage of Participants With Anti-HLX105 Antibodies (ADA) and Percentage of Participants With Neutralizing Antibodies (NAb)
Time Frame: Up to approximately 2 years
Up to approximately 2 years
Change From Baseline in PD-1 Receptor Occupancy on Peripheral Blood T Cells
Time Frame: Up to approximately 2 years

Receptor occupancy will be expressed as the percentage of PD-1 receptors occupied by the study drug. Changes from baseline will be calculated at each scheduled post-dose assessment.

Up to approximately 2 years
Change From Baseline in Peripheral Blood Interferon Gamma Concentration
Time Frame: Up to approximately 2 years
Up to approximately 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 30, 2026

Primary Completion (Estimated)

November 30, 2027

Study Completion (Estimated)

November 30, 2028

Study Registration Dates

First Submitted

November 4, 2026

First Submitted That Met QC Criteria

November 17, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • HLX105-FIH101

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.